[
  {
    "ts": null,
    "headline": "Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern",
    "summary": "Explore Alnylam Pharmaceuticals' outlook as TTR franchise growth, competitive pressures, and valuation create a potential 'buy the dip' investment.",
    "url": "https://finnhub.io/api/news?id=ab654d49604b8e16c69380a5b9a91387ab53a2601ff159875215c43d87d3b5fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765665900,
      "headline": "Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern",
      "id": 137780050,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1914834329/image_1914834329.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Explore Alnylam Pharmaceuticals' outlook as TTR franchise growth, competitive pressures, and valuation create a potential 'buy the dip' investment.",
      "url": "https://finnhub.io/api/news?id=ab654d49604b8e16c69380a5b9a91387ab53a2601ff159875215c43d87d3b5fa"
    }
  },
  {
    "ts": null,
    "headline": "Forget Teladoc and Buy This Healthcare Stock Instead",
    "summary": "It's time for investors to give up on the telemedicine leader.",
    "url": "https://finnhub.io/api/news?id=b25b6025eb692ddbccad36fd511f8d763254715c35bfd189e7340e4b39b91293",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765627980,
      "headline": "Forget Teladoc and Buy This Healthcare Stock Instead",
      "id": 137792588,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "It's time for investors to give up on the telemedicine leader.",
      "url": "https://finnhub.io/api/news?id=b25b6025eb692ddbccad36fd511f8d763254715c35bfd189e7340e4b39b91293"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Right Long-Term Strategy",
    "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
    "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765600404,
      "headline": "Eli Lilly: The Right Long-Term Strategy",
      "id": 137774561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1874681159/image_1874681159.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
      "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
    "summary": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
    "url": "https://finnhub.io/api/news?id=e9fb7539331c732e4deaf7a25050e9c42ce4f727463c3f6dace5c8bacfcf5b38",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765584443,
      "headline": "Morgan Stanley Maintains Pfizer (PFE) Equal-Weight Recommendation",
      "id": 137772402,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=e9fb7539331c732e4deaf7a25050e9c42ce4f727463c3f6dace5c8bacfcf5b38"
    }
  }
]